Brief: USPTO Grants Acurx Pharmaceuticals New Patent For Ibezapolstat To Treat CDI
17/07/2024 12:19
July 17 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* USPTO GRANTS ACURX PHARMACEUTICALS NEW PATENT FOR
IBEZAPOLSTAT
TO TREAT CDI WHILE REDUCING RECURRENCE OF INFECTION AND
IMPROVING HEALTH OF THE GUT MICROBIOME
Source text for Eikon: ID:nPn3nkN8Ca
Further company coverage: ACXP.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program